Spironolactone decreases the formation of prostaglandins and related substances from arachidonic acid in rat vascular rings and human platelets

This publication has 17 references indexed in Scilit:

• Modification by prostaglandins E1 and E2, indomethacin, and arachidonic acid of the vasoconstrictor responses of the isolated perfused rabbit and rat mesenteric arteries to adrenergic stimuli.
  Circulation Research, 1976
• Molecular modifications of anti-aldosterone compounds: Effects on affinity of spirolactones for renal aldosterone receptors
  Biochemical Pharmacology, 1974
• Spironolactone as a Nonspecific Treatment for Primary Aldosteronism
  Circulation, 1973
• The Diagnostic and Therapeutic Value of Spironolactone in Patients with Systemic Hypertension
  Nephron, 1972
• The effect of spironolactone on digital vascular reactivity in essential hypertension
  American Heart Journal, 1968
• The pharmacology and clinical use of rauwolfia, hydralazine, thiazides, and aldosterone antagonists in arterial hypertension
  Progress in Cardiovascular Diseases, 1966
• Aldosterone and its antagonists
  Clinical Pharmacology & Therapeutics, 1965
• DECREASED EFFECTIVENESS OF ALDOSTERONE ON ACTIVE SODIUM TRANSPORT BY THE ISOLATED TOAD BLADDER IN THE PRESENCE OF OTHER STEROIDS
  Acta Endocrinologica, 1964
• Aldosterone Antagonists
  Archives of internal medicine (1960), 1958
• EFFECT OF AN ALDOSTERONE ANTAGONIST ON SODIUM AND POTASSIUM EXCRETION IN PRIMARY HYPERALDOSTERONISM
  Journal of Clinical Endocrinology & Metabolism, 1958